

CONTENTS

FOREWORD	xxi
<i>Lisa A. Shipley</i>	
PREFACE	xxv
<i>Donglu Zhang and Sekhar Surapaneni</i>	
CONTRIBUTORS	xxvii
PART A ADME: OVERVIEW AND CURRENT TOPICS	1
1 Regulatory Drug Disposition and NDA Package Including MIST	3
<i>Sekhar Surapaneni</i>	
1.1 Introduction	3
1.2 Nonclinical Overview	5
1.3 PK	5
1.4 Absorption	5
1.5 Distribution	6
1.5.1 Plasma Protein Binding	6
1.5.2 Tissue Distribution	6
1.5.3 Lacteal and Placental Distribution Studies	7
1.6 Metabolism	7
1.6.1 <i>In vitro</i> Metabolism Studies	7
1.6.2 Drug–Drug Interaction Studies	8
1.6.3 <i>In vivo</i> Metabolism (ADME) Studies	10
1.7 Excretion	11
1.8 Impact of Metabolism Information on Labeling	11
1.9 Conclusions	12
References	12
2 Optimal ADME Properties for Clinical Candidate and Investigational New Drug (IND) Package	15
<i>Rajinder Bhardwaj and Gamini Chandrasena</i>	
2.1 Introduction	15
2.2 NCE and Investigational New Drug (IND) Package	16

2.3	ADME Optimization	17
2.3.1	Absorption	18
2.3.2	Metabolism	20
2.3.3	PK	22
2.4	ADME Optimization for CNS Drugs	23
2.5	Summary	24
	References	25
3	Drug Transporters in Drug Interactions and Disposition	29
	<i>Imad Hanna and Ryan M. Pelis</i>	
3.1	Introduction	29
3.2	ABC Transporters	31
3.2.1	Pgp (MDR1, ABCB1)	31
3.2.2	BCRP (ABCG2)	32
3.2.3	MRP2 (ABCC2)	32
3.3	SLC Transporters	33
3.3.1	OCT1 (SLC22A1) and OCT2 (SLC22A2)	34
3.3.2	MATE1 (SLC47A1) and MATE2K (SLC47A2)	35
3.3.3	OAT1 (SLC22A6) and OAT3 (SLC22A8)	36
3.3.4	OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9)	37
3.4	<i>In vitro</i> Assays in Drug Development	39
3.4.1	Considerations for Assessing Candidate Drugs as Inhibitors	39
3.4.2	Considerations for Assessing Candidate Drugs as Substrates	39
3.4.3	Assay Systems	40
3.5	Conclusions and Perspectives	45
	References	46
4	Pharmacological and Toxicological Activity of Drug Metabolites	55
	<i>W. Griffith Humphreys</i>	
4.1	Introduction	55
4.2	Assessment of Potential for Active Metabolites	56
4.2.1	Detection of Active Metabolites during Drug Discovery	58
4.2.2	Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures	58
4.2.3	Methods for Generation of Metabolites	59
4.3	Assessment of the Potential Toxicology of Metabolites	59
4.3.1	Methods to Study the Formation of Reactive Metabolites	60
4.3.2	Reactive Metabolite Studies: <i>In vitro</i>	61
4.3.3	Reactive Metabolite Studies: <i>In vivo</i>	61
4.3.4	Reactive Metabolite Data Interpretation	61
4.3.5	Metabolite Contribution to Off-Target Toxicities	62
4.4	Safety Testing of Drug Metabolites	62
4.5	Summary	63
	References	63
5	Improving the Pharmaceutical Properties of Biologics in Drug Discovery: Unique Challenges and Enabling Solutions	67
	<i>Jiwen Chen and Ashok Dongre</i>	
5.1	Introduction	67
5.2	Pharmacokinetics	68
5.3	Metabolism and Disposition	70

5.4	Immunogenicity	71
5.5	Toxicity and Preclinical Assessment	74
5.6	Comparability	74
5.7	Conclusions	75
	References	75
6	Clinical Dose Estimation Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation	79
	<i>Lingling Guan</i>	
6.1	Introduction	79
6.2	Biomarkers in PK and PD	80
6.2.1	PK	80
6.2.2	PD	81
6.2.3	Biomarkers	81
6.3	Model-Based Clinical Drug Development	83
6.3.1	Modeling	83
6.3.2	Simulation	84
6.3.3	Population Modeling	85
6.3.4	Quantitative Pharmacology (QP) and Pharmacometrics	85
6.4	First-in-Human Dose	86
6.4.1	Drug Classification Systems as Tools for Development	86
6.4.2	Interspecies and Allometric Scaling	87
6.4.3	Animal Species, Plasma Protein Binding, and <i>in vivo–in vitro</i> Correlation	88
6.5	Examples	89
6.5.1	First-in-Human Dose	89
6.5.2	Pediatric Dose	90
6.6	Discussion and Conclusion	90
	References	93
7	Pharmacogenomics and Individualized Medicine	95
	<i>Anthony Y.H. Lu and Qiang Ma</i>	
7.1	Introduction	95
7.2	Individual Variability in Drug Therapy	95
7.3	We Are All Human Variants	96
7.4	Origins of Individual Variability in Drug Therapy	96
7.5	Genetic Polymorphism of Drug Targets	97
7.6	Genetic Polymorphism of Cytochrome P450s	98
7.7	Genetic Polymorphism of Other Drug Metabolizing Enzymes	100
7.8	Genetic Polymorphism of Transporters	100
7.9	Pharmacogenomics and Drug Safety	101
7.10	Warfarin Pharmacogenomics: A Model for Individualized Medicine	102
7.11	Can Individualized Drug Therapy Be Achieved?	104
7.12	Conclusions	104
	Disclaimer	105
	Contact Information	105
	References	105
8	Overview of Drug Metabolism and Pharmacokinetics with Applications in Drug Discovery and Development in China	109
	<i>Chang-Xiao Liu</i>	
8.1	Introduction	109

8.2	PK–PD Translation Research in New Drug Research and Development	109
8.3	Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME/T) Studies in Drug Discovery and Early Stage of Development	110
8.4	Drug Transporters in New Drug Research and Development	111
8.5	Drug Metabolism and PK Studies for New Drug Research and Development	113
8.5.1	Technical Guidelines for PK Studies in China	113
8.5.2	Studies on New Molecular Entity (NME) Drugs	114
8.5.3	PK Calculation Program	117
8.6	Studies on the PK of Biotechnological Products	117
8.7	Studies on the PK of TCMs	118
8.7.1	The Challenge in PK Research of TCMs	118
8.7.2	New Concept on PK Markers	120
8.7.3	Identification of Nontarget Components from Herbal Preparations	122
8.8	PK and Bioavailability of Nanomaterials	123
8.8.1	Research and Development of Nanopharmaceuticals	123
8.8.2	Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials	123
8.8.3	Biodistribution and Biodegradation	123
8.8.4	Doxorubicin Polyethylene Glycol-Phosphatidylethanolamine (PEG-PE) Nanoparticles	124
8.8.5	Micelle-Encapsulated Alprostadil (M-Alp)	124
8.8.6	Paclitaxel Magnetoliposomes	125
	References	125

PART B ADME SYSTEMS AND METHODS 129

9 Technical Challenges and Recent Advances of Implementing Comprehensive ADMET Tools in Drug Discovery 131

Jianling Wang and Leslie Bell

9.1	Introduction	131
9.2	“A” Is the First Physiological Barrier That a Drug Faces	131
9.2.1	Solubility and Dissolution	131
9.2.2	GI Permeability and Transporters	136
9.3	“M” Is Frequently Considered Prior to Distribution Due to the “First-Pass” Effect	139
9.3.1	Hepatic Metabolism	139
9.3.2	CYPs and Drug Metabolism	140
9.4	“D” Is Critical for Correctly Interpreting PK Data	142
9.4.1	Blood/Plasma Impact on Drug Distribution	142
9.4.2	Plasma Stability	143
9.4.3	PPB	144
9.4.4	Blood/Plasma Partitioning	144
9.5	“E”: The Elimination of Drugs Should Not Be Ignored	145
9.6	Metabolism- or Transporter-Related Safety Concerns	146
9.7	Reversible CYP Inhibition	147
9.7.1	<i>In vitro</i> CYP Inhibition	147

9.7.2	Human Liver Microsomes (HLM) + Prototypical Probe Substrates with Quantification by LC-MS	147
9.7.3	Implementation Strategy	149
9.8	Mechanism-Based (Time-Dependent) CYP Inhibition	149
9.8.1	Characteristics of CYP3A TDI	150
9.8.2	<i>In vitro</i> Screening for CYP3A TDI	150
9.8.3	Inactivation Rate (k_{obs})	150
9.8.4	IC ₅₀ -Shift	151
9.8.5	Implementation Strategy	152
9.9	CYP Induction	152
9.10	Reactive Metabolites	153
9.10.1	Qualitative <i>in vitro</i> Assays	153
9.10.2	Quantitative <i>in vitro</i> Assay	154
9.11	Conclusion and Outlook	154
	Acknowledgments	155
	References	155
10	Permeability and Transporter Models in Drug Discovery and Development	161
	<i>Praveen V. Balimane, Yong-Hae Han, and Saeho Chong</i>	
10.1	Introduction	161
10.2	Permeability Models	162
10.2.1	PAMPA	162
10.2.2	Cell Models (Caco-2 Cells)	162
10.2.3	P-glycoprotein (Pgp) Models	162
10.3	Transporter Models	163
10.3.1	Intact Cells	164
10.3.2	Transfected Cells	165
10.3.3	<i>Xenopus</i> Oocyte	165
10.3.4	Membrane Vesicles	165
10.3.5	Transgenic Animal Models	166
10.4	Integrated Permeability–Transporter Screening Strategy	166
	References	167
11	Methods for Assessing Blood–Brain Barrier Penetration in Drug Discovery	169
	<i>Li Di and Edward H. Kerns</i>	
11.1	Introduction	169
11.2	Common Methods for Assessing BBB Penetration	170
11.3	Methods for Determination of Free Drug Concentration in the Brain	170
11.3.1	<i>In vivo</i> Brain PK in Combination with <i>in vitro</i> Brain Homogenate Binding Studies	171
11.3.2	Use of CSF Drug Concentration as a Surrogate for Free Drug Concentration in the Brain	171
11.4	Methods for BBB Permeability	172
11.4.1	<i>In situ</i> Brain Perfusion Assay	172
11.4.2	High-throughput PAMPA-BBB	173
11.4.3	Lipophilicity (LogD _{7.4})	173
11.5	Methods for Pgp Efflux Transport	173
11.6	Conclusions	174
	References	174

12	Techniques for Determining Protein Binding in Drug Discovery and Development	177
	<i>Tom Lloyd</i>	
12.1	Introduction	177
12.2	Overview	178
12.3	Equilibrium Dialysis	179
12.4	Ultracentrifugation	180
12.5	Ultrafiltration	181
12.6	Microdialysis	182
12.7	Spectroscopy	182
12.8	Chromatographic Methods	183
12.9	Summary Discussion	183
	Acknowledgment	185
	References	185
13	Reaction Phenotyping	189
	<i>Chun Li and Nataraj Kalyanaraman</i>	
13.1	Introduction	189
13.2	Initial Considerations	190
13.2.1	Clearance Mechanism	190
13.2.2	Selecting the Appropriate <i>in vitro</i> System	191
13.2.3	Substrate Concentration	191
13.2.4	Effect of Incubation Time and Protein Concentration	192
13.2.5	Determination of Kinetic Constant K_m and V_{max}	192
13.2.6	Development of Analytical Methods	192
13.3	CYP Reaction Phenotyping	193
13.3.1	Specific Chemical Inhibitors	194
13.3.2	Inhibitory CYP Antibodies	195
13.3.3	Recombinant CYP Enzymes	196
13.3.4	Correlation Analysis for CYP Reaction Phenotyping	198
13.3.5	CYP Reaction Phenotyping in Drug Discovery versus Development	198
13.4	Non-P450 Reaction Phenotyping	199
13.4.1	FMOs	199
13.4.2	MAOs	200
13.4.3	AO	200
13.5	UGT Conjugation Reaction Phenotyping	201
13.5.1	Initial Considerations in UGT Reaction Phenotyping	202
13.5.2	Experimental Approaches for UGT Reaction Phenotyping	202
13.5.3	Use of Chemical Inhibitors for UGTs	203
13.5.4	Correlation Analysis for UGT Reaction Phenotyping	204
13.6	Reaction Phenotyping for Other Conjugation Reactions	204
13.7	Integration of Reaction Phenotyping and Prediction of DDI	205
13.8	Conclusion	205
	References	206
14	Fast and Reliable CYP Inhibition Assays	213
	<i>Ming Yao, Hong Cai, and Mingshe Zhu</i>	
14.1	Introduction	213
14.2	CYP Inhibition Assays in Drug Discovery and Development	215

14.3	HLM Reversible CYP Inhibition Assay Using Individual Substrates	217
14.3.1	Choice of Substrate and Specific Inhibitors	217
14.3.2	Optimization of Incubation Conditions	217
14.3.3	Incubation Procedures	217
14.3.4	LC-MS/MS Analysis	221
14.3.5	Data Calculation	221
14.4	HLM RI Assay Using Multiple Substrates (Cocktail Assays)	222
14.4.1	Choice of Substrate and Specific Inhibitors	222
14.4.2	Optimization of Incubations	223
14.4.3	Incubation Procedures	223
14.4.4	LC-MS/MS Analysis	224
14.4.5	Data Calculation	224
14.5	Time-Dependent CYP Inhibition Assay	226
14.5.1	IC ₅₀ Shift Assay	226
14.5.2	K _I and K _{inact} Measurements	227
14.5.3	Data Calculation	228
14.6	Summary and Future Directions	228
	References	230
15	Tools and Strategies for the Assessment of Enzyme Induction in Drug Discovery and Development	233
	<i>Adrian J. Fretland, Anshul Gupta, Peijuan Zhu, and Catherine L. Booth-Genthe</i>	
15.1	Introduction	233
15.2	Understanding Induction at the Gene Regulation Level	233
15.3	<i>In silico</i> Approaches	234
15.3.1	Model-Based Drug Design	234
15.3.2	Computational Models	234
15.4	<i>In vitro</i> Approaches	235
15.4.1	Ligand Binding Assays	235
15.4.2	Reporter Gene Assays	236
15.5	<i>In vitro</i> Hepatocyte and Hepatocyte-Like Models	238
15.5.1	Hepatocyte Cell-Based Assays	238
15.5.2	Hepatocyte-Like Cell-Based Assays	239
15.6	Experimental Techniques for the Assessment of Induction in Cell-Based Assays	239
15.6.1	mRNA Quantification	240
15.6.2	Protein Quantification	241
15.6.3	Assessment of Enzyme Activity	244
15.7	Modeling and Simulation and Assessment of Risk	244
15.8	Analysis of Induction in Preclinical Species	245
15.9	Additional Considerations	245
15.10	Conclusion	246
	References	246
16	Animal Models for Studying Drug Metabolizing Enzymes and Transporters	253
	<i>Kevin L. Salyers and Yang Xu</i>	
16.1	Introduction	253
16.2	Animal Models of DMEs	253
16.2.1	Section Objectives	253
16.2.2	<i>In vivo</i> Models to Study the Roles of DMEs in Determining Oral Bioavailability	254

16.2.3	<i>In vivo</i> Models to Predict Human Drug Metabolism and Toxicity	257
16.2.4	<i>In vivo</i> Models to Study the Regulation of DMEs	259
16.2.5	<i>In vivo</i> Models to Predict Induction-Based DDIs in Humans	260
16.2.6	<i>In vivo</i> Models to Predict Inhibition-Based DDIs in Humans	261
16.2.7	<i>In vivo</i> Models to Study the Function of DMEs in Physiological Homeostasis and Human Diseases	262
16.2.8	Summary	263
16.3	Animal Models of Drug Transporters	263
16.3.1	Section Objectives	263
16.3.2	<i>In vivo</i> Models to Characterize Transporters in Drug Absorption	264
16.3.3	<i>In vivo</i> Models Used to Study Transporters in Brain Penetration	266
16.3.4	<i>In vivo</i> Models to Assess Hepatic and Renal Transporters	268
16.3.5	Summary	270
16.4	Conclusions and the Path Forward	270
	Acknowledgments	271
	References	271
17	Milk Excretion and Placental Transfer Studies	277
	<i>Matthew Hoffmann and Adam Shilling</i>	
17.1	Introduction	277
17.2	Compound Characteristics That Affect Placental Transfer and Lacteal Excretion	277
17.2.1	Passive Diffusion	278
17.2.2	Drug Transporters	279
17.2.3	Metabolism	280
17.3	Study Design	281
17.3.1	Placental Transfer Studies	281
17.3.2	Lacteal Excretion Studies	285
17.4	Conclusions	289
	References	289
18	Human Bile Collection for ADME Studies	291
	<i>Suresh K. Balani, Lisa J. Christopher, and Donglu Zhang</i>	
18.1	Introduction	291
18.2	Physiology	291
18.3	Utility of the Biliary Data	292
18.4	Bile Collection Techniques	293
18.4.1	Invasive Methods	293
18.4.2	Noninvasive Methods	293
18.5	Future Scope	297
	Acknowledgment	297
	References	297
PART C	ANALYTICAL TECHNOLOGIES	299
19	Current Technology and Limitation of LC-MS	301
	<i>Cornelis E.C.A. Hop</i>	
19.1	Introduction	301

19.2	Sample Preparation	302
19.3	Chromatography Separation	302
19.4	Mass Spectrometric Analysis	304
19.5	Ionization	304
19.6	MS Mode versus MS/MS or MS ⁿ Mode	305
19.7	Mass Spectrometers: Single and Triple Quadrupole Mass Spectrometers	306
19.8	Mass Spectrometers: Three-Dimensional and Linear Ion Traps	308
19.9	Mass Spectrometers: Time-of-Flight Mass Spectrometers	308
19.10	Mass Spectrometers: Fourier Transform and Orbitrap Mass Spectrometers	309
19.11	Role of LC-MS in Quantitative <i>in vitro</i> ADME Studies	309
19.12	Quantitative <i>in vivo</i> ADME Studies	311
19.13	Metabolite Identification	312
19.14	Tissue Imaging by MS	313
19.15	Conclusions and Future Directions	313
	References	314
20	Application of Accurate Mass Spectrometry for Metabolite Identification	317
	<i>Zhoupeng Zhang and Kaushik Mitra</i>	
20.1	Introduction	317
20.2	High-Resolution/Accurate Mass Spectrometers	317
20.2.1	Linear Trap Quadrupole-Orbitrap (LTQ-Orbitrap) Mass Spectrometer	318
20.2.2	Q-tof and Triple Time-of-Flight (TOF)	318
20.2.3	Hybrid Ion Trap Time-of-Flight Mass Spectrometer (IT-tof)	318
20.3	Postacquisition Data Processing	318
20.3.1	MDF	319
20.3.2	Background Subtraction Software	319
20.4	Utilities of High-Resolution/Accurate Mass Spectrometry (HRMS) in Metabolite Identification	320
20.4.1	Fast Metabolite Identification of Metabolically Unstable Compounds	320
20.4.2	Identification of Unusual Metabolites	322
20.4.3	Identification of Trapped Adducts of Reactive Metabolites	325
20.4.4	Analysis of Major Circulating Metabolites of Clinical Samples of Unlabeled Compounds	327
20.4.5	Applications in Metabolomics	328
20.5	Conclusion	328
	References	329
21	Applications of Accelerator Mass Spectrometry (AMS)	331
	<i>Xiaomin Wang, Voon Ong, and Mark Seymour</i>	
21.1	Introduction	331
21.2	Bioanalytical Methodology	332
21.2.1	Sample Preparation	332
21.2.2	AMS Instrumentation	332
21.2.3	AMS Analysis	333
21.3	AMS Applications in Mass Balance/Metabolite Profiling	334

21.4	AMS Applications in Pharmacokinetics	335
21.5	Conclusion	337
	References	337
22	Radioactivity Profiling	339
	<i>Wing Wah Lam, Jose Silva, and Heng-Keang Lim</i>	
22.1	Introduction	339
22.2	Radioactivity Detection Methods	340
	22.2.1 Conventional Technologies	340
	22.2.2 Recent Technologies	341
22.3	AMS	346
22.4	Intracavity Optogalvanic Spectroscopy	349
22.5	Summary	349
	Acknowledgments	349
	References	349
23	A Robust Methodology for Rapid Structure Determination of Microgram-Level Drug Metabolites by NMR Spectroscopy	353
	<i>Kim A. Johnson, Stella Huang, and Yue-Zhong Shu</i>	
23.1	Introduction	353
23.2	Methods	354
	23.2.1 Liver Microsome Incubations of Trazodone	354
	23.2.2 HPLC and Metabolite Purification	354
	23.2.3 HPLC-MS/MS	355
	23.2.4 NMR	355
23.3	Trazodone and Its Metabolism	355
23.4	Trazodone Metabolite Generation and NMR Sample Preparation	356
23.5	Metabolite Characterization	356
23.6	Comparison with Flow Probe and LC-NMR Methods	361
23.7	Metabolite Quantification by NMR	361
23.8	Conclusion	361
	References	362
24	Supercritical Fluid Chromatography	363
	<i>Jun Dai, Yingru Zhang, David B. Wang-Iverson, and Adrienne A. Tymiak</i>	
24.1	Introduction	363
24.2	Background	363
24.3	SFC Instrumentation and General Considerations	364
	24.3.1 Detectors Used in SFC	365
	24.3.2 Mobile Phases Used in SFC	366
	24.3.3 Stationary Phases Used in SFC	367
	24.3.4 Comparison of SFC with Other Chromatographic Techniques	367
	24.3.5 Selectivity in SFC	368
24.4	SFC in Drug Discovery and Development	369
	24.4.1 SFC Applications for Pharmaceuticals and Biomolecules	370
	24.4.2 SFC Chiral Separations	372
	24.4.3 SFC Applications for High-Throughput Analysis	374
	24.4.4 Preparative Separations	375
24.5	Future Perspective	375
	References	376

25	Chromatographic Separation Methods	381
	<i>Wenyang Jian, Richard W. Edom, Zhongping (John) Lin, and Naidong Weng</i>	
25.1	Introduction	381
25.1.1	A Historical Perspective	381
25.1.2	The Need for Separation in ADME Studies	381
25.1.3	Challenges for Current Chromatographic Techniques in Support of ADME Studies	382
25.2	LC Separation Techniques	383
25.2.1	Basic Practical Principles of LC Separation Relevant to ADME Studies	383
25.2.2	Major Modes of LC Frequently Used for ADME Studies	385
25.2.3	Chiral LC	387
25.3	Sample Preparation Techniques	388
25.3.1	Off-Line Sample Preparation	388
25.3.2	Online Sample Preparation	389
25.3.3	Dried Blood Spots (DBS)	390
25.4	High-Speed LC-MS Analysis	390
25.4.1	UHPLC	390
25.4.2	Monolithic Columns	391
25.4.3	Fused-Core Silica Columns	392
25.4.4	Fast Separation Using HILIC	393
25.5	Orthogonal Separation	394
25.5.1	Orthogonal Sample Preparation and Chromatography	394
25.5.2	2D-LC	395
25.6	Conclusions and Perspectives	395
	References	396
26	Mass Spectrometric Imaging for Drug Distribution in Tissues	401
	<i>Daniel P. Magparangalan, Timothy J. Garrett, Dieter M. Drexler, and Richard A. Yost</i>	
26.1	Introduction	401
26.1.1	Imaging Techniques for ADMET Studies	401
26.1.2	Mass Spectrometric Imaging (MSI) Background	401
26.2	MSI Instrumentation	403
26.2.1	Microprobe Ionization Sources	403
26.2.2	Mass Analyzers	404
26.3	MSI Workflow	406
26.3.1	Postdissection Tissue/Organ Preparation and Storage	406
26.3.2	Tissue Sectioning and Mounting	406
26.3.3	Tissue Section Preparation, MALDI Matrix Selection, and Deposition	407
26.3.4	Spatial Resolution: Relationship between Laser Spot Size and Raster Step Size	407
26.4	Applications of MSI for <i>in situ</i> ADMET Tissue Studies	408
26.4.1	Determination of Drug Distribution and Site of Action	408
26.4.2	Analysis of Whole-Body Tissue Sections Utilizing MSI	409
26.4.3	Increasing Analyte Specificity for Mass Spectrometric Images	411
26.4.4	DESI Applications for MSI	412
26.5	Conclusions	413
	References	414

27	Applications of Quantitative Whole-Body Autoradiography (QWBA) in Drug Discovery and Development	419
	<i>Lifei Wang, Haizheng Hong, and Donglu Zhang</i>	
27.1	Introduction	419
27.2	Equipment and Materials	419
27.3	Study Designs	420
	27.3.1 Choice of Radiolabel	420
	27.3.2 Choice of Animals	420
	27.3.3 Dose Selection, Formulation, and Administration	420
27.4	QWBA Experimental Procedures	420
	27.4.1 Embedding	420
	27.4.2 Whole-Body Sectioning	421
	27.4.3 Whole-Body Imaging	421
	27.4.4 Quantification of Radioactivity Concentration	421
27.5	Applications of QWBA	421
	27.5.1 Case Study 1: Drug Delivery to Pharmacology Targets	421
	27.5.2 Case Study 2: Tissue Distribution and Metabolite Profiling	422
	27.5.3 Case Study 3: Tissue Distribution and Protein Covalent Binding	424
	27.5.4 Case Study 4: Rat Tissue Distribution and Human Dosimetry Calculation	425
	27.5.5 Case Study 5: Placenta Transfer and Tissue Distribution in Pregnant Rats	430
27.6	Limitations of QWBA	432
	References	433
PART D	NEW AND RELATED TECHNOLOGIES	435
28	Genetically Modified Mouse Models in ADME Studies	437
	<i>Xi-Ling Jiang and Ai-Ming Yu</i>	
28.1	Introduction	437
28.2	Drug Metabolizing Enzyme Genetically Modified Mouse Models	438
	28.2.1 CYP1A1/CYP1A2	438
	28.2.2 CYP2A6/Cyp2a5	438
	28.2.3 CYP2C19	439
	28.2.4 CYP2D6	439
	28.2.5 CYP2E1	440
	28.2.6 CYP3A4	440
	28.2.7 Cytochrome P450 Reductase (CPR)	441
	28.2.8 Glutathione S-Transferase pi (GSTP)	441
	28.2.9 Sulfotransferase 1E1 (SULT1E1)	442
	28.2.10 Uridine 5'-Diphospho-Glucuronosyltransferase 1 (UGT1)	442
28.3	Drug Transporter Genetically Modified Mouse Models	442
	28.3.1 P-Glycoprotein (Pgp/MDR1/ABCB1)	442
	28.3.2 Multidrug Resistance-Associated Proteins (MRP/ABCC)	442
	28.3.3 Breast Cancer Resistance Protein (BCRP/ABCG2)	444
	28.3.4 Bile Salt Export Pump (BSEP/ABCB11)	444
	28.3.5 Peptide Transporter 2 (PEPT2/SLC15A2)	444
	28.3.6 Organic Cation Transporters (OCT/SLC22A)	445

28.3.7	Multidrug and Toxin Extrusion 1 (MATE1/SLC47A1)	445
28.3.8	Organic Anion Transporters (OAT/SLC22A)	445
28.3.9	Organic Anion Transporting Polypeptides (OATP/SLCO)	445
28.3.10	Organic Solute Transporter α (OST α)	446
28.4	Xenobiotic Receptor Genetically Modified Mouse Models	446
28.4.1	Aryl Hydrocarbon Receptor (AHR)	446
28.4.2	Pregnane X Receptor (PXR/NR1I2)	446
28.4.3	Constitutive Androstane Receptor (CAR/NR1I3)	446
28.4.4	Peroxisome Proliferator-Activated Receptor α (PPAR α /NR1C1)	447
28.4.5	Retinoid X Receptor α (RXR α /NR2B1)	447
28.5	Conclusions	448
	References	448
29	Pluripotent Stem Cell Models in Human Drug Development	455
	<i>David C. Hay</i>	
29.1	Introduction	455
29.2	Human Drug Metabolism and Compound Attrition	455
29.3	Human Hepatocyte Supply	456
29.4	hESCs	456
29.5	hESC HLC Differentiation	456
29.6	iPSCs	456
29.7	CYP P450 Expression in Stem Cell-Derived HLCs	457
29.8	Tissue Culture Microenvironment	457
29.9	Culture Definition for Deriving HLCs from Stem Cells	457
29.10	Conclusion	457
	References	458
30	Radiosynthesis for ADME Studies	461
	<i>Brad D. Maxwell and Charles S. Elmore</i>	
30.1	Background and General Requirements	461
30.1.1	Food and Drug Administration (FDA) Guidance	461
30.1.2	Third Clinical Study after Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Studies	462
30.1.3	Formation of the ADME Team	462
30.1.4	Human Dosimetry Projection	462
30.1.5	cGMP Synthesis Conditions	462
30.1.6	Formation of One Covalent Bond	462
30.2	Radiosynthesis Strategies and Goals	463
30.2.1	Determination of the Most Suitable Radioisotope for the Human ADME Study	463
30.2.2	Synthesize the API with the Radiolabel in the Most Metabolically Stable Position	463
30.2.3	Incorporate the Radiolabel as Late in the Synthesis as Possible	465
30.2.4	Use the Radiolabeled Reagent as the Limiting Reagent	465
30.2.5	Consider Alternative Labeled Reagents and Strategies	466
30.2.6	Develop One-Pot Reactions and Minimize the Number of Purification Steps	467
30.2.7	Safety Considerations	467
30.3	Preparation and Synthesis	467
30.3.1	Designated cGMP-Like Area	467
30.3.2	Cleaning	467

30.3.3	Glassware	468
30.3.4	Equipment and Calibration of Analytical Instruments	468
30.3.5	Reagents and Substrates	468
30.3.6	Practice Reactions	468
30.3.7	Actual Radiolabel Synthesis	468
30.4	Analysis and Product Release	469
30.4.1	Validated HPLC Analysis	469
30.4.2	Orthogonal HPLC Method	469
30.4.3	Liquid Chromatography-Mass Spectrometry (LC-MS) Analysis	469
30.4.4	Proton and Carbon-13 NMR	469
30.4.5	Determination of the SA of the High Specific Activity API	469
30.4.6	Mixing of the High Specific Activity API with Unlabeled Clinical-Grade API	470
30.4.7	Determination of the SA of the Low Specific Activity API	470
30.4.8	Other Potential Analyses	470
30.4.9	Establishment of Use Date and Use Date Extensions	470
30.4.10	Analysis and Release of the Radiolabeled Drug Product	471
30.5	Documentation	471
30.5.1	QA Oversight	471
30.5.2	TSE and BSE Assessment	471
30.6	Summary	471
	References	471
31	Formulation Development for Preclinical <i>in vivo</i> Studies	473
	<i>Yuan-Hon Kiang, Darren L. Reid, and Janan Jona</i>	
31.1	Introduction	473
31.2	Formulation Consideration for the Intravenous Route	473
31.3	Formulation Consideration for the Oral, Subcutaneous, and Intraperitoneal Routes	474
31.4	Special Consideration for the Intraperitoneal Route	475
31.5	Solubility Enhancement	475
31.6	pH Manipulation	476
31.7	Cosolvents Utilization	477
31.8	Complexation	479
31.9	Amorphous Form Approach	479
31.10	Improving the Dissolution Rate	479
31.11	Formulation for Toxicology Studies	479
31.12	Timing and Assessment of Physicochemical Properties	480
31.13	Critical Issues with Solubility and Stability	481
	31.13.1 Solubility	481
	31.13.2 Chemical Stability Assessment	481
	31.13.3 Monitoring of the Physical and Chemical Stability	482
31.14	General and Quick Approach for Formulation Identification at the Early Discovery Stages	482
	References	482
32	<i>In vitro</i> Testing of Proarrhythmic Toxicity	485
	<i>Haoyu Zeng and Jiasheng Kang</i>	
32.1	Objectives, Rationale, and Regulatory Compliance	485
32.2	Study System and Design	486

32.2.1	The Gold Standard Manual Patch Clamp System	486
32.2.2	Semiautomated System	487
32.2.3	Automated System	487
32.2.4	Comparison between Isolated Cardiomyocytes and Stably Transfected Cell Lines	489
32.3	Good Laboratory Practice (GLP)-hERG Study	489
32.4	Medium-Throughput Assays Using PatchXpress as a Case Study	490
32.5	Nonfunctional and Functional Assays for hERG Trafficking	491
32.6	Conclusions and the Path Forward	491
	References	492
33	Target Engagement for PK/PD Modeling and Translational Imaging Biomarkers	493
	<i>Vanessa N. Barth, Elizabeth M. Joshi, and Matthew D. Silva</i>	
33.1	Introduction	493
33.2	Application of LC-MS/MS to Assess Target Engagement	494
33.2.1	Advantages and Disadvantages of Technology and Study Designs	494
33.3	LC-MS/MS-Based RO Study Designs and Their Calculations	494
33.3.1	Sample Analysis	496
33.3.2	Comparison and Validation versus Traditional Approaches	497
33.4	Leveraging Target Engagement Data for Drug Discovery from an Absorption, Distribution, Metabolism, and Excretion (ADME) Perspective	497
33.4.1	Drug Exposure Measurement	497
33.4.2	Protein Binding and Unbound Concentrations	498
33.4.3	Metabolism and Active Metabolites	500
33.5	Application of LC-MS/MS to Discovery Novel Tracers	502
33.5.1	Characterization of the Dopamine D ₂ PET Tracer Raclopride by LC-MS/MS	502
33.5.2	Discovery of Novel Tracers	503
33.6	Noninvasive Translational Imaging	503
33.7	Conclusions and the Path Forward	507
	References	508
34	Applications of iRNA Technologies in Drug Transporters and Drug Metabolizing Enzymes	513
	<i>Mingxiang Liao and Cindy Q. Xia</i>	
34.1	Introduction	513
34.2	Experimental Designs	514
34.2.1	siRNA Design	514
34.2.2	Methods for siRNA Production	515
34.2.3	Controls and Delivery Methods Selection	517
34.2.4	Gene Silencing Effects Detection	520
34.2.5	Challenges in siRNA	524
34.3	Applications of RNAi in Drug Metabolizing Enzymes and Transporters	527
34.3.1	Applications of Silencing Drug Transporters	527
34.3.2	Applications of Silencing Drug Metabolizing Enzymes	534
34.3.3	Applications of Silencing Nuclear Receptors (NRs)	534
34.3.4	Applications in <i>in vivo</i>	535

34.4	Conclusions	538
	Acknowledgment	539
	References	539
Appendix	Drug Metabolizing Enzymes and Biotransformation Reactions	545
	<i>Natalia Penner, Caroline Woodward, and Chandra Prakash</i>	
A.1	Introduction	545
A.2	Oxidative Enzymes	547
A.2.1	P450	547
A.2.2	FMOs	548
A.2.3	MAOs	549
A.2.4	Molybdenum Hydroxylases (AO and XO)	549
A.2.5	ADHs	550
A.2.6	ALDHs	550
A.3	Reductive Enzymes	550
A.3.1	AKRs	550
A.3.2	AZRs and NTRs	551
A.3.3	QRs	551
A.3.4	ADH, P450, and NADPH-P450 Reductase	551
A.4	Hydrolytic Enzymes	551
A.4.1	Epoxide Hydrolases (EHs)	551
A.4.2	Esterases and Amidases	552
A.5	Conjugative (Phase II) DMEs	553
A.5.1	UGTs	553
A.5.2	SULTs	553
A.5.3	Methyltransferases (MTs)	553
A.5.4	NATs	554
A.5.5	GSTs	554
A.5.6	Amino Acid Conjugation	555
A.6	Factors Affecting DME Activities	555
A.6.1	Species and Gender	556
A.6.2	Polymorphism of DMEs	556
A.6.3	Comedication and Diet	556
A.7	Biotransformation Reactions	557
A.7.1	Oxidation	557
A.7.2	Reduction	560
A.7.3	Conjugation Reactions	561
A.8	Summary	561
	Acknowledgment	562
	References	562
INDEX		567